Fundraising Fox
Inmune Bio
NASDAQ: INMBLa Jolla, US · Founded 2015 · Nevada corporation
Find your way into Inmune Bio
Sign up to see every warm intro you have to Inmune Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Inmune Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
INmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
Founders & leadership
Inmune Bio was founded in 2015 by Mark Lowdell, Raymond Tesi, and David J. Moss.
RT
Raymond TesiChief Executive Officer
DJ
David J. MossCEOCEO of INmune Bio, a clinical-stage biotechnology company developing immunotherapies for neurodegenerative and psychiatric diseases.
JK
J. Kelly GanjeiNamed on SEC filing
TR
Terry R. KnappNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$8M disclosed across 2 rounds · 2017–2019
▶$4.7MraisedMay 2019 · 5 investors · BiotechnologyRule 506(b)
▶$4.7MraisedMay 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Raymond J. TesiExecutive Officer, Director
- David MossExecutive Officer
- Mark LowdellExecutive Officer
- J. Kelly GanjeiDirector
- Timothy SchroederDirector
- David SzymkowskiDirector
- Scott JudaDirector
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- First sale
- Apr 2019
- Incorporated
- Corporation, Nevada, 2015
- Federal exemptions
- 06b
▶$3.3MraisedJul 2017 · 29 investors · BiotechnologyRule 506(b)
▶$3.3MraisedJul 2017 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark LowdellExecutive Officer, Director
- J. Kelly GanjeiDirector
- David J. MossExecutive Officer, Director
- Raymond TesiExecutive Officer, Director
- Terry R. KnappDirector
- Offering amount
- $5M
- Amount sold
- $3.3M
- Minimum investment
- $10K
- Sales commissions
- $47.5K
- Placement agents
- Westpark Capital, Inc.
- First sale
- Mar 2017
- Incorporated
- Corporation, Nevada, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
InimmuneInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
ImmuneeringImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
ImmunaiImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
InfinimmuneInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
Companies working in the same space as Inmune Bio.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Inmune Bio do?
- INmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
- Who founded Inmune Bio?
- Inmune Bio was founded by Mark Lowdell, Raymond Tesi, David J. Moss in 2015.
- How much funding has Inmune Bio raised?
- Inmune Bio has disclosed $8M raised across 2 rounds.
- Where is Inmune Bio headquartered?
- Inmune Bio is headquartered in La Jolla, US.